Posting of Annual Report and AGM Notice

8 October 2020

Diurnal Group plc

("Diurnal" or the "Company")

Posting of Annual Report and AGM Notice

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that its Annual Report and Accounts for the year ending 30 June 2020, together with the Notice of Annual General Meeting (AGM), have today been posted to shareholders.

The documents are being made available on the investor relations section of the Company's website, www.diurnal.co.uk.

The Company's AGM will be held at 11:00 GMT at the Company's London office at Regus Woburn Place, 16 Upper Woburn Place, London, WC1H 0BS on Tuesday 20 November 2020. Due to the ongoing COVID-19 pandemic and in line with UK Government advice, the Board has decided to run the 2020 AGM as a closed meeting and shareholders will not be able to attend.

In the light of these measures, the Board strongly encourages shareholders to vote by proxy in accordance with the instructions in the Notice of AGM. Shareholders can submit questions to the Company ahead of the AGM as per instructions included within the Notice of AGM.

Notes to Editors

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-headquartered, European specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia and adrenal insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information about Diurnal, please visit www.diurnal.co.uk